AnGes Inc - Company Profile
Powered by 
All the data and insights you need on AnGes Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date AnGes Inc Strategy Report
- Understand AnGes Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
View up-to-date information on AnGes Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| WO2022170216A3 | Application | OMNI 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, AND 131-138 CRISPR NUCLEASES | C12N9/22 | September 15, 2022 |
| WO2022192508A1 | Application | STRATEGIES FOR KNOCK-INS AT C3 SAFE HARBOR SITES | September 15, 2022 | |
| EP4054654A1 | Application | DIFFERENTIELLES KNOCKOUT EINES ALLELS EINES HETEROZYGOTEN ELAN-GENS UNTER VERWENDUNG VON GUIDES MIT 21-30-NUKLEOTIDEN IN LÄNGE | A61K48/005; A61P7/00; C12N15/111; C12N15/70; C12N15/907; C12N2310/20; C12N2320/34; C12N9/22; C12N9/6448; C12Y304/21037 | September 14, 2022 |
| US20220267777A1 | Application | DIFFERENTIAL KNOCKOUT OF A HETEROZYGOUS ALLELE OF RPE65 | C12N15/1137; C12N2310/20; C12N2320/34; C12Y301/01064 | August 25, 2022 |
| WO2022170216A2 | Application | OMNI 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, AND 131-138 CRISPR NUCLEASES | C12N9/22 | August 11, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward